PALLAS: PALbociclib CoLlaborative adjuvant study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone HR1/HER2-early breast cancer

被引：0

作者：

Mayer, E. L. ^{[1
]}

Demichele, A. M. ^{[2
]}

Pfeiler, G. ^{[3
]}

Barry, W. ^{[4
]}

Metzger, O. ^{[5
]}

Rastogi, P. ^{[6
]}

Symmans, F. ^{[7
]}

Burstein, H. J. ^{[4
]}

Miller, K. ^{[8
]}

Loibl, S. ^{[9
]}

Schmatloch, S. ^{[10
]}

Goulioti, T. ^{[11
]}

Zardavas, D. ^{[11
]}

Fesl, C. ^{[12
]}

Koehler, M. ^{[13
]}

Bartlett, C. Huang ^{[13
]}

Huang, X. ^{[14
]}

Piccart, M. ^{[15
]}

Winer, E. ^{[4
]}

Gnant, M. ^{[16
,17
]}

机构：

[1] Harvard Med Sch, Dana Farber Canc Inst, Breast Oncol Ctr, Boston, MA USA

[2] Univ Penn, Perelman Ctr Adv Med, Philadelphia, PA 19104 USA

[3] Med Univ Vienna, Gyneol & Obstet, Vienna, Austria

[4] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[5] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[6] Univ Pittsburgh Sch Hlth Sci, Div Hematol Oncol, Pittsburgh, PA USA

[7] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA

[8] Indiana Univ Sch Med, Hematol Oncol, Indianapolis, IN 46202 USA

[9] German Breast Grp GBG Forsch GmbH, Med & Res, Neu Isenburg, Germany

[10] Elisabeth Hosp, Senol, Kassel, Germany

[11] Breast Int Grp, Brussels, Belgium

[12] Austrian Breast & Colorectal Canc Study Grp ABCSG, Stat, Vienna, Austria

[13] Pfizer, Oncol, New York, NY USA

[14] Pfizer, Oncol, San Diego, CA USA

[15] Inst Jules Bordet, Chemotherapy Dept, Brussels, Belgium

[16] Med Univ Vienna, Dept Surg, Vienna, Austria

[17] Med Univ Vienna, Comprehens Canc Ctr, Vienna, Austria

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

215TiP

引用

页数：1

共 50 条

[31] eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.
Tolaney, Sara M.
Fallowfield, Lesley
Kaufman, Peter A.
Ciruelos, Eva M.
Gainford, Mary Corona
Lu, Yi
Hurt, Karla
Wasserstrom, Heather Ann
Chen, Yanyun
Goel, Shom
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[32] EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2-early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET
Jhaveri, Komal
O'Shaughnessy, Joyce
Andre, Fabrice
Goetz, Matthew P.
Harbeck, Nadia
Martin, Miguel
Bidard, Francois-Clement
Thomas, Zachary M.
Young, Suzanne
Ismail-Khan, Roohi
Smyth, Lillian M.
Gnant, Michael
CANCER RESEARCH, 2023, 83 (05)
[33] Patient-reported outcomes in high-risk HR+ /HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study
Garcia-Saenz, Jose Angel
Marme, Frederik
Untch, Michael
Bonnefoi, Herve
Kim, Sung-Bae
Bear, Harry
Mc Carthy, Nicole
Gelmon, Karen
Martin, Miguel
Kelly, Catherine M.
Reimer, Toralf
Toi, Masakazu
Law, Ernest
Bhattacharyya, Helen
Gnant, Michael
Makris, Andreas
Seiler, Sabine
Burchardi, Nicole
Nekljudova, Valentina
Loibl, Sibylle
Rugo, Hope S.
EUROPEAN JOURNAL OF CANCER, 2024, 196
[34] A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
Hortobagyi, G. N.
Lacko, A.
Sohn, J.
Cruz, F.
Borrego, M. Ruiz
Manikhas, A.
Park, Y. Hee
Stroyakovskiy, D.
Hurvitz, S.
Barrios, C.
Untch, M.
Moroose, R.
Yardley, D. A.
Visco, F.
Chia, S.
Huang, C. -s.
Fasching, P. A.
Parnizari, F.
Crown, J.
Zarate, J. P.
Bardia, A.
Loi, S.
Li, Z.
Martin, M.
Xu, B.
Im, S. -a.
Waters, S.
Chakravartty, A.
Slamon, D.
ANNALS OF ONCOLOGY, 2025, 36 (02) : 149 - 157
[35] Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2-metastatic breast cancer patients compared to endocrine therapy alone - A large institutional study
Raghavendra, Akshara Singareeka
Ha, Min Jin
Kettner, Nicole M.
Damodaran, Senthil
Layman, Rachel
Hunt, Kelly K.
Shen, Yu
Tripathy, Debu
Keyomarsi, Khandan
CANCER RESEARCH, 2022, 82 (04)
[36] Efficacy and safety analysis of Chinese patients in monarchE: Abemaciclib combined with adjuvant endocrine therapy for high risk HR+, HER2-early breast cancer.
Shao Zhimin
Zhang, Qingyuan
Song, Chuan-gui
Ouyang, Quchang
Liu, Zhenzhen
Liu, Qiang
Feng, Jifeng
Chiu, Joanne Wing Yan
Tseng, Ling-Ming
Qian, Chenxi
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[37] ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2-early breast cancer.
Harbeck, Nadia
Gluz, Oleg
Christgen, Matthias
Graeser, Monika
Hilpert, Felix
Krauss, Katja
Kreipe, Hans Heinrich
Nitz, Ulrike
Kates, Ronald E.
Schinkoethe, Timo
Wuerstlein, Rachel
Kuemmel, Sherko
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[38] Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy
Sverrisdóttir, A
Fornander, T
Jacobsson, H
von Schoultz, E
Rutqvist, LE
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) : 3694 - 3699
[39] Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2-early breast cancer: ADAPTcycle.
Harbeck, Nadia
Gluz, Oleg
Christgen, Matthias
Braun, Michael
Thill, Marc
Wimberger, Pauline
Luedtke-Heckenkamp, Kerstin
Graeser, Monika
Hilpert, Felix
Bjelic-Radisic, Vesna
Krauss, Katja
Warm, Mathias
Zaiss, Matthias R.
Hartkopf, Andreas D.
Just, Marianne
Kreipe, Hans Heinrich
Nitz, Ulrike
Eulenburg, Christine Zu
Wuerstlein, Rachel
Kuemmel, Sherko
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[40] Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer
Chapman, Judith-Anne W.
Meng, Daniel
Shepherd, Lois
Parulekar, Wendy
Ingle, James N.
Muss, Hyman B.
Palmer, Michael
Yu, Changhong
Goss, Paul E.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (04): : 252 - 260

← 1 2 3 4 5 →